Global expansion Sim&Cure has recently secured financing rounds totaling around €20 million and actively targets international growth, with a focus on China and the Asia-Pacific region, presenting a clear opportunity to approach regional healthcare distributors, system integrators, and hospital networks seeking advanced neurovascular software.

Strategic partnerships Longstanding collaborations with Philips and other leading laboratories/hospitals indicate openness to OEM-style partnerships and co-development; potential sales opportunities exist in joint offerings, integration with existing imaging/therapy platforms, and bundled solutions for neurovascular planning.

Clinical validation Winner of i-Lab and i-Nov with strong clinical and academic ties suggests a credible value proposition for health systems; leverage these achievements to engage decision-makers in hospitals and research centers prioritizing digital twin AI tools for endovascular treatment.

Growth-ready readiness Recent leadership addition and expanding R&D and commercial teams signal organizational capacity to scale; approach hiring-focused buyers, procurement leaders, and regional heads in high-growth markets with scalable licensing and service models.

Medtech positioning Focused on neurovascular planning and clinician workflow alignment using Digital Twin and AI, the company sits at the intersection of software-as-a-medical-device capabilities; target hospital networks, academic centers, and medtech distributors seeking advanced digital workflow enhancements.